Evidence mapPaperPMID 36949174Full record

ArticleScientific reports2023

Enhancing a SARS-CoV-2 nucleocapsid antigen test sensitivity with cost efficient strategy through a cotton intermembrane insertion.

Diego Rinaldi Pavesi Nicollete, Rafael Benedetti, Beatriz Arruda Valença, Keyla Kaori Kuniyoshi, Thainá Caroline Schuartz de Jesus, Ava Gevaerd, Erika Bergamo Santiago, Bernardo Montesanti Machado de Almeida, Sérgio Renato Rogal Júnior, Marcus Vinícius Mazega Figueredo

Open access · goldFull text read
In one paragraph

Article in Scientific reports, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 10 papers.

0numbers the graph read from it
0cells of the map it votes in
10citing papers in PubMed
2.5field-weighted citation impact, top 11% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

10 citing papers in PubMed, 13 citations in OpenAlex.

  1. Article
  2. Review
  3. Design of a lateral flow assay targeting the conserved NIID_2019-nCoV_N gene region for molecular viral diagnosis.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2025
    Article
  4. Optical lateral flow assays in early diagnosis of SARS-CoV-2 infection.Analytical sciences : the international journal of the Japan Society for Analytical Chemistry · 2024
    Review
  5. Article
  6. Article
  7. Article
  8. Review
  9. Article
  10. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

10 authors at 1 institution in 1 country.

Diego Rinaldi Pavesi NicolleteResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil. diego.nicollete@hilab.com.br.
Rafael BenedettiResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Beatriz Arruda ValençaResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Keyla Kaori KuniyoshiResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Thainá Caroline Schuartz de JesusResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Ava GevaerdResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Erika Bergamo SantiagoResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Bernardo Montesanti Machado de AlmeidaResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Sérgio Renato Rogal JúniorResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Marcus Vinícius Mazega FigueredoResearch and Development Department, Hilab, Hilab Campus, José A. Possebom, 800, Curitiba, Paraná, 81270-185, Brazil.
Spectral Imaging Laboratory (United States) · US

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

Lateral flow antigen tests have been widely used in the Covid-19 pandemic, allowing faster diagnostic test results and preventing further viral spread through isolation of infected individuals. Accomplishment of this screening must be performed with tests that show satisfactory sensitivity in order to successfully detect the target protein and avoid false negatives. The aim of this study was to create a lateral flow test that could detect SARS-CoV-2 nucleocapsid protein in low concentrations that were comparable to the limits of detection claimed by existing tests from the market. To do so, several adjustments were necessary during research and development of the prototypes until they were consistent with these criteria. The proposed alternatives of increasing the test line antibody concentration and addition of an intermembrane between the conjugate pad and the nitrocellulose membrane were able to increase the sensitivity four-fold and generate a new rapid test prototype called "lateral flow intermembrane immunoassay test" (LFIIT). This prototype showed an adequate limit of detection (2.0 ng mL

Indexed as

COVID-19SARS-CoV-2AntigensGossypiumHumansImmunoassayNucleocapsidPandemicsSensitivity and SpecificityAntigens

Identifiers

PMID36949174
PMCPMC10031715
OpenAlexW4360600513

What Socratic holds

Textfull text, public
LicenceCC BY
measurements read40
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.